First Trust Advisors’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $54.6M | Buy |
288,247
+40,663
| +16% | +$7.65M | 0.03% | 587 |
|
|
2026
Q1 | $48.7M | Sell |
247,584
-188,244
| -43% | -$36.3M | 0.03% | 590 |
|
|
2025
Q4 | $80.1M | Sell |
435,828
-67,047
| -13% | -$11.8M | 0.06% | 399 |
|
|
2025
Q3 | $77.2M | Sell |
502,875
-51,857
| -9% | -$7.85M | 0.06% | 409 |
|
|
2025
Q2 | $77.5M | Buy |
554,732
+108,797
| +24% | +$15.2M | 0.06% | 386 |
|
|
2025
Q1 | $65.6M | Sell |
445,935
-43,337
| -9% | -$6.27M | 0.06% | 434 |
|
|
2024
Q4 | $64.1M | Buy |
489,272
+41,298
| +9% | +$5.78M | 0.06% | 424 |
|
|
2024
Q3 | $69.8M | Buy |
447,974
+12,603
| +3% | +$2.03M | 0.07% | 357 |
|
|
2024
Q2 | $67.9M | Sell |
435,371
-180,417
| -29% | -$27.1M | 0.07% | 310 |
|
|
2024
Q1 | $83.4M | Sell |
615,788
-79,692
| -11% | -$10.6M | 0.08% | 270 |
|
|
2023
Q4 | $93.7M | Buy |
695,480
+47,826
| +7% | +$6.22M | 0.1% | 238 |
|
|
2023
Q3 | $87.7M | Buy |
647,654
+11,591
| +2% | +$1.58M | 0.1% | 240 |
|
|
2023
Q2 | $91M | Sell |
636,063
-23,497
| -4% | -$3.46M | 0.1% | 252 |
|
|
2023
Q1 | $91.6M | Buy |
659,560
+31,231
| +5% | +$4.2M | 0.11% | 258 |
|
|
2022
Q4 | $85.2M | Sell |
628,329
-118,639
| -16% | -$14.9M | 0.1% | 290 |
|
|
2022
Q3 | $81.9M | Buy |
746,968
+176,099
| +31% | +$22.3M | 0.11% | 264 |
|
|
2022
Q2 | $75.4M | Sell |
570,869
-20,612
| -3% | -$2.7M | 0.09% | 307 |
|
|
2022
Q1 | $78.5M | Buy |
591,481
+57,116
| +11% | +$6.85M | 0.08% | 336 |
|
|
2021
Q4 | $62.3M | Buy |
534,365
+30,886
| +6% | +$3.63M | 0.06% | 443 |
|
|
2021
Q3 | $60.5M | Buy |
503,479
+661
| +0.1% | +$76.9K | 0.07% | 406 |
|
|
2021
Q2 | $60.2M | Sell |
502,818
-62,902
| -11% | -$6.9M | 0.07% | 412 |
|
|
2021
Q1 | $56.3M | Buy |
565,720
+25,497
| +5% | +$2.56M | 0.07% | 419 |
|
|
2020
Q4 | $54M | Buy |
+540,223
| New | +$57.2M | 0.07% | 399 |
|
|
2020
Q3 | – | Sell |
-2,107
| Closed | -$223K | – | 2316 |
|
|
2020
Q2 | $223K | Sell |
2,107
-342
| -14% | -$35.3K | ﹤0.01% | 2219 |
|
|
2020
Q1 | $219K | Sell |
2,449
-425
| -15% | -$40K | ﹤0.01% | 2169 |
|
|
2019
Q4 | $287K | Buy |
+2,874
| New | +$271K | ﹤0.01% | 2284 |
|
|
2017
Q2 | – | Sell |
-279,565
| Closed | -$17.4M | – | 2368 |
|
|
2017
Q1 | $17.4M | Buy |
279,565
+5,774
| +2% | +$336K | 0.05% | 570 |
|
|
2016
Q4 | $15M | Buy |
273,791
+82,497
| +43% | +$4.68M | 0.04% | 595 |
|
|
2016
Q3 | $12.6M | Sell |
191,294
-909
| -0.5% | -$59.4K | 0.04% | 639 |
|
|
2016
Q2 | $11.6M | Buy |
192,203
+44,723
| +30% | +$2.6M | 0.04% | 642 |
|
|
2016
Q1 | $8.31M | Buy |
147,480
+33,226
| +29% | +$2M | 0.03% | 739 |
|
|
2015
Q4 | $7.76M | Buy |
114,254
+35,799
| +46% | +$2.35M | 0.02% | 781 |
|
|
2015
Q3 | $4.99M | Sell |
78,455
-12,785
| -14% | -$841K | 0.01% | 975 |
|
|
2015
Q2 | $5.81M | Sell |
91,240
-4,354
| -5% | -$298K | 0.02% | 1021 |
|
|
2015
Q1 | $6.54M | Sell |
95,594
-2,287
| -2% | -$159K | 0.02% | 934 |
|
|
2014
Q4 | $6.89M | Buy |
97,881
+16,083
| +20% | +$1.15M | 0.02% | 892 |
|
|
2014
Q3 | $5.84M | Buy |
81,798
+6,346
| +8% | +$464K | 0.02% | 954 |
|
|
2014
Q2 | $5.61M | Sell |
75,452
-12,192
| -14% | -$881K | 0.02% | 937 |
|
|
2014
Q1 | $5.69M | Sell |
87,644
-2,455
| -3% | -$159K | 0.03% | 914 |
|
|
2013
Q4 | $5.35M | Sell |
90,099
-6,873
| -7% | -$373K | 0.03% | 924 |
|
|
2013
Q3 | $5.04M | Buy |
96,972
+2,064
| +2% | +$104K | 0.03% | 876 |
|
|
2013
Q2 | $4.49M | Buy |
+94,908
| New | +$4.83M | 0.03% | 828 |
|
Other funds holding AZN
EP
IA
First Trust Advisors's AZN Position: Q2 2026 in Review
First Trust Advisors increased its AstraZeneca (AZN) stake by 16% in Q2 2026, buying an estimated $7.65M and bringing the position to 288,247 shares worth $54.6M. The position accounts for 0.03% of the portfolio, ranked #587.
First Trust Advisors first reported a position in AZN in Q2 2013 and has held it in 42 quarters since. The position peaked at $93.7M in Q4 2023. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- First Trust Advisors held 288,247 shares of AstraZeneca worth $54.6M as of Q2 2026.
- First Trust Advisors bought 40,663 AstraZeneca shares in Q2 2026, an estimated $7.65M.
- AstraZeneca made up 0.03% of First Trust Advisors's portfolio in Q2 2026, its #587 holding.
- First Trust Advisors first reported a position in AstraZeneca in Q2 2013 and has held it in 42 quarters since.
- First Trust Advisors's AstraZeneca position peaked at $93.7M in Q4 2023.
- 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on First Trust Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.